Back to Search
Start Over
Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma.
- Source :
-
Radiation Oncology . 10/2/2020, Vol. 15 Issue 1, p1-9. 9p. - Publication Year :
- 2020
-
Abstract
- <bold>Background: </bold>This study aimed to assess the effectiveness and cost-effectiveness of nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).<bold>Methods: </bold>LA-NPC patients treated between October 2013 and December 2016 were retrospectively reviewed. A well-balanced cohort of patients who received nimotuzumab in addition to standard treatment (n = 50) and patients who did not receive nimotuzumab (n = 100) was selected using propensity score-matching method (1:2 ratio) for the cost-effectiveness analysis.<bold>Results: </bold>Compared with concurrent chemoradiotherapy (CCRT) alone, addition of nimotuzumab to CCRT significantly improved the 3-year overall survival (OS) (98.00% vs. 91.00%, P = 0.032). On multivariate analysis, nimotuzumab (hazard ratio = 0.124, 95% confidence interval: 0.017-0.902, P = 0.039) showed prognostic significance for OS. No serious treatment-related adverse events were observed in the nimotuzumab group (P > 0.05). Cost-effectiveness analysis revealed that addition of nimotuzumab increased the average treatment costs by $14,364.63. The additional cost for every one percent increase in OS rate was $ 2,052.09.<bold>Conclusion: </bold>Addition of nimotuzumab to CCRT for LA-NPC confers significant survival benefits; however, it is not cost-effective. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1748717X
- Volume :
- 15
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Radiation Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 146197043
- Full Text :
- https://doi.org/10.1186/s13014-020-01674-5